Class IIOngoingD-0471-2026
Drug recall · April 22, 2026
Semaglutide-Glycine-Cyanocobalamin Injectable recall
Why: Lack of Assurance of Sterility
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Semaglutide-Glycine-Cyanocobalamin Injectable, 2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials, Rx only, Northwest Compounders, Beaverton, OR
- Lots / codes
Lot Number [email protected]
- Quantity
- 91 vials
- Company
- Payless Compounders, LLC, Beaverton, OR
- Distribution
- OR
- Initiated
- March 6, 2026 · Voluntary: Firm initiated
- Classified
- April 13, 2026
- Reported
- April 22, 2026
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Glycine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.